Russell Bradley Named President & General Manager of CNSideDr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of ...

Zongertinib, an investigational treatment for HER2-mutant advanced NSCLC, has received FDA priority review, showing positive ...

The global Metastatic Cancer Drugs market was valued at US$ 72.64 billion in 2023 and is projected to reach US$ 136.95 billion by 2032, growing at a CAGR of 26.3% from 2024 to 2032. Read the Market ...

Russell Bradley Named President & General Manager of CNSide Dr. Marc Hedrick, Rick Hawkins, and Russell Bradley Join CNSide Board of Directors Dr. Jonathan Stein Appointed CNSide Medical Director AUST ...

Therapeutic Nuclear Medicines MarketThe therapeutic nuclear medicine market is projected to grow from USD 1.32 billion in ...

为探究乳腺癌脑转移（BCBMs）治疗策略变化对患者结局的影响，意大利和法国多家机构研究人员开展相关研究。结果发现仅 HR-/HER2 + 患者总生存期改善。该研究对优化治疗、评估预后意义重大，值得科研读者一读。